Browsing Tag
Phelan-McDermid syndrome
5 posts
Neuren Pharmaceuticals (ASX: NEU) begins first-ever Phase 3 trial in Phelan-McDermid syndrome
Neuren Pharmaceuticals Limited has dosed the first patient in the first Phase 3 Phelan-McDermid syndrome trial. See why it matters for rare disease drug development.
Can this A$653m raise turn PYC Therapeutics (ASX: PYC) into a global RNA frontrunner?
PYC Therapeutics is raising A$653M to fund four RNA therapies into human efficacy trials. Find out what this means for investors and the biotech sector.
Zelira Therapeutics (ASX:ZLD) secures $33m to advance HOPE 1 autism therapy through U.S. FDA trials
Find out how Zelira’s US$33M SPV deal with ThirdGate Capital is reshaping its FDA strategy for HOPE 1 and shaking up the autism biotech space.
Neuren Pharmaceuticals secures third FDA Fast Track for NNZ-2591 as shares rise 4.21%
Find out how Neuren Pharmaceuticals is expanding FDA Fast Track coverage for NNZ‑2591 across rare disorders like PMS, AS, and Pitt Hopkins.
Neuren Pharmaceuticals advances NNZ-2591 for Phelan-McDermid syndrome to Phase 3 clinical trial
Neuren Pharmaceuticals has secured approval from the United States Food and Drug Administration (FDA) to progress into the…